Though not in line with existing literature, if successful in AR-negative PCa, targeting BRD9 could be clinically very useful: following the introduction and approval of second-generation anti-androgens, the percentage of patients with AR-negative tumours has increased from 11.7% (1996–2011) to 36.6% (2012–2016) [65]. The gene discussed is BRD9; the disease is posterior cortical atrophy.